ReviewSubstance use & misuse2005
Combination treatment for nicotine dependence: state of the science.
Review in Substance use & misuse, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00749658 (Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence
Who cites it
7 citing papers in PubMed, 22 citations in OpenAlex.
- Why two smoking cessation agents work better than one: role of craving suppression.Journal of consulting and clinical psychology · 2012Trial
- A test of motivational plus nicotine replacement interventions for HIV positive smokers.AIDS and behavior · 2009Trial
- Current Smoking: An Independent Predictor of Elevated A1C in Persons With Type 2 Diabetes.The Diabetes educator · 2019Article
- Psychological factors associated with smoking and quitting: addiction map of Turkey study.Neuropsychiatric disease and treatment · 2019Article
- Review
- Treating smoking dependence in depressed alcoholics.Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism · 2006Review
- Plasticity of addiction: a mesolimbic dopamine short-circuit?The American journal on addictionsReview
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Both nicotine replacement and sustained-release buproprion double the odds of achieving short- and moderate-term abstinence from nicotine. However, questions remain about the efficacy of combining pharmacotherapies. Our purposes were to review the evidence for (1) combined pharmacotherapy and (2) multimodal treatment combining pharmacotherapy and behavioral treatment and to recommend combinations of treatments to reduce nicotine dependence. Combining first-line pharmacotherapies with each other or with investigational drugs shows little benefit. In contrast, trials combining specific behavioral treatments with first-line pharmacotherapies show enhanced smoking cessation rates, but benefits are not seen in all populations. We recommend future directions for research, including better specification of behavioral components and further examination of the length and timing of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.